Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma - Summary - MDSpire

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

  • By

  • Eric Jurgens

  • Tala Shekarkhand

  • Colin Rueda

  • David Nemirovsky

  • Andriy Derkach

  • Ross S. Firestone

  • Kevin Miller

  • Bruno Almeida Costa

  • Sridevi Rajeeve

  • Alexander M. Lesokhin

  • Neha Korde

  • Carlyn R. Tan

  • Hamza Hashmi

  • Hani Hassoun

  • Kylee Maclachlan

  • Urvi A. Shah

  • Malin Hultcrantz

  • Issam Hamadeh

  • Sergio A. Giralt

  • Gunjan L. Shah

  • Heather J. Landau

  • Michael Scordo

  • Saad Z. Usmani

  • Sham Mailankody

  • Zainab Shahid

  • November 1, 2025

  • 0 min

Share

Objective:

To assess the incidence and risk factors of cytomegalovirus (CMV) reactivation in patients with relapsed/refractory multiple myeloma undergoing treatment with bispecific antibodies, highlighting the importance of routine CMV monitoring.

Key Findings:
  • CMV reactivation occurred in 28% of patients at Day 90 and 36% at Day 180, with significant implications for patient management.
  • 41% of patients showed CMV detection at Day 90 and 51% at Day 180.
  • Four patients developed clinically significant CMV infections, including one case of CMV esophagitis, highlighting the need for vigilant monitoring.
Interpretation:

The study highlights a significant incidence of CMV reactivation during bispecific antibody therapy, suggesting the need for routine CMV monitoring and potential preemptive treatment strategies to improve patient outcomes.

Limitations:
  • The study was conducted at a single center, which may limit generalizability and introduce variability in treatment practices.
  • CMV testing was not routinely performed in prior clinical trials, potentially underestimating the incidence.
Conclusion:

CMV reactivation is a notable complication in patients with RRMM treated with bispecific antibodies, warranting careful monitoring and management, and further research on effective CMV management strategies.

Original Source(s)

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

  • by Eric Jurgens, Tala Shekarkhand, Colin Rueda, David Nemirovsky, Andriy Derkach, Ross S. Firestone, Kevin Miller, Bruno Almeida Costa, Sridevi Rajeeve, Alexander M. Lesokhin, Neha Korde, Carlyn R. Tan, Hamza Hashmi, Hani Hassoun, Kylee Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam Hamadeh, Sergio A. Giralt, Gunjan L. Shah, Heather J. Landau, Michael Scordo, Saad Z. Usmani, Sham Mailankody, Zainab Shahid

  • November 1, 2025

Related Content

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database